table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
Immunosuppressants drugs
adalimumab Fakharian
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...
tocilizumab REMAP-CAP ... CORIMUNO-TOCI-ICU ... COVACTA ... Veiga Rosas ... CORIMUNO-TOCI-1 ... Talaschian MARIPOSA
canakinumab CAN-COVID
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ...
ruxolitinib Cao
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...

5 studies excluded by filtering options 0

5180 TACROVID, 2021 000selection pending
5398 Ana-COVID (Huet), 2020 0133selection pending
6359 Kooistra, 2020 0100selection pending
6789 Amra, 2021 113high risk of bias
6879 Kumar, 2021 113high risk of bias

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons